1.
PRECISION ONCOLOGY ADOPTION:
The future is now

2.
2
No two patients are the same
Copyright © 2020 Accenture. All rights reserved.
Historically Recently Today The Future
ORGAN-BASED BIOMARKER
STRATIFIED
GENOMICS-
BASED
MULTIOMICS
DRIVEN
That’s why the future of healthcare lies in customization, with decisions and practices
tailored to the individual patient.

3.
3
Precision medicine holds great promise for
reshaping the way we treat cancer
Copyright © 2020 Accenture. All rights reserved.
Standard cancer therapies are ineffective in an average of three-quarters of
patients(1) one of the highest therapy failure rates for all diseases.
Effectively applied, precision oncology should drastically
enhance the way drugs are developed, the way cancer is
treated, and (most importantly) the health outcomes that
patients can realistically hope for.
(1) Spear, B. B. et al. Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201–204 (2001)

4.
4
But precision oncology is still
largely unused by physicians
Copyright © 2020 Accenture. All rights reserved.
In our survey of 130 oncologists from the
United States and Europe, 70% say precision
oncology is emerging and applied in their
practices to some degree. But…
routinely
participate in
molecular
tumor boards
routinely use
clinical decision
support (CDS)
tools
routinely match
targeted therapies
to genomic
alteration
Only 14% Only 18% Only 41%

5.
5Copyright © 2020 Accenture. All rights reserved.
DATA
A data foundation to
support their adoption
and use in clinical practice
CLINICAL DECISION
SUPPORT
Tools and guidelines to support
their decision making and
mitigate uncertainty
EVOLVED EDUCATION
Comprehensive understanding
of precision oncology to aid
implementation
How can we make
precision oncology
work at the clinical
practice level?
Oncologists told us they need
three things to speed adoption.

6.
DATA
CLINICAL
DECISION
SUPPORT
EVOLVED
EDUCATION
6Copyright © 2020 Accenture. All rights reserved.
The foundation for precision oncology
DATA
Create transparency into
patient benefits including
when and how to apply
precision oncology
To get clinical value from the data and encourage cross-organizational
adoption, common approaches to data collection, data quality, and
accreditation are needed.
01 02
More than 90% of oncologists say data should be shared
across borders.
Benefits of sharing access to cohort data:
Review longitudinal studies
of comparable cases to
support decisions that are
in patients’ best interests

7.
DATA
CLINICAL
DECISION
SUPPORT
EVOLVED
EDUCATION
7Copyright © 2020 Accenture. All rights reserved.
CDS tools provide doctors with intelligently filtered information at
important moments along the care pathway to enhance clinical
decisions and improve health outcomes.
Most oncologists expect CDS tools to:
Minimize the
risk of error
Facilitate the process
of staying up to date
Increase available time
for direct patient care
83% 82% 66%
Mitigating uncertainty
CLINICAL DECISION SUPPORT:

8.
DATA
EVOLVED
EDUCATION
8Copyright © 2020 Accenture. All rights reserved.
Detailed
understanding
of molecular
mechanisms and
genomic alterations
CLINICAL
DECISION
SUPPORT
Deeper
understanding of
advanced analytics,
tools, algorithms and
statistical principles
Understanding the
technological dimension
covering algorithms
related to ML, AI, and new
technologies emerging in
cancer therapy
Understanding the fundamentals
EVOLVED EDUCATION:
Ongoing education is vital to adoption as treatment options
and technologies multiply, becoming too numerous and
complex to keep up with.
Oncologists will need to master new skillsets:

9.
9
We believe widespread adoption hinges on
four essential steps
Copyright © 2020 Accenture. All rights reserved.
01
02
03
04
Build the basics
Think beyond
borders
Reimagine
medical
education
Make healthcare
professionals’
lives easier
Address the complexity of precision oncology.
Create a collaborative ecosystem.
Support oncologists to master the new skills required.
Integrate new technology into physicians’ daily workflows.

10.
To leverage the full potential of precision oncology,
we must get to work.
Start by reading our full report
The time is now to chart a new course.
The future of oncology depends on it.